FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than February 4, 1997.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Todd E. Arendt, and Revocable Trust Agreement of Angela D. Hulin, both of Gilman, Iowa; to each acquire an additional 25.00 percent, for a total of 50.22 percent, of the voting shares of Gilman Investment Co., Oskaloosa, Iowa, and thereby indirectly acquire Citizens Savings Bank, Gilman, Iowa.

Board of Governors of the Federal Reserve System, January 15, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–1470 Filed 1-21-97; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30 DAY–26]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639–7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

The following requests have been submitted for review since the last publication date on January 16, 1997.

Proposed Project

Studies of Immunotoxicity in Occupational Groups—(0920–0333)—Reinstatement—A number of chemicals to which U.S. workers are potentially exposed, including metals such as lead and beryllium and solvents such as carbon tetrachloride, have been found to be immunotoxic in experimental animals. There is little data on immunosuppression, hypersensitivity or autoimmune disease in workers exposed to chemicals that are immunotoxic in experimental animals. NIOSH has undertaken a coordinated series of studies to focus on immune-system effects related to specific chemical exposures in the workplace. In the previous three years, NIOSH conducted studies of lead and egg protein exposed workers.

In this reinstatement of the program, it is anticipated that up to six additional research studies will be conducted under this program. Examples of chemicals for which studies are being considered are latex, silica, and solvents. In most of these studies, the immune function of a group of workers exposed to the chemical of interest, and not exposed to any other known or potential immunotoxins, will be compared to the immune function in a group of individuals with no occupational exposure to known or suspected immunotoxins. In some studies, the immune function in a group of individuals will be compared before and after they have exposure to the potential immunotoxin. The primary information collected will be data on the level of exposure to the potential immunotoxin (as measured in the air in the breathing zone of the respondent, and/or in the respondent's blood or urine) and data on specific markers of the status of the immune system from blood or saliva samples provided by the subjects. The questionnaire data will be directed at demographic, lifestyle, and medical factors (other than the exposure or condition of interest) which may influence the function of the immune system. In selected studies, the questionnaire will be used to assess the presence of respiratory symptoms, dermatologic conditions and/or reproductive effects, if the literature indicates a potential relationship to these health problems. Study populations will be identified through telephone contact and follow-up site visits (if needed) with workplace facilities that use the chemical of interest. The total annual burden is 1607.

Respondent (form)	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Interview and blood collection	600	1	1	600
Additional interview module (respiratory, dermatologic, or reproductive)	600	1	.5	300
Peak flow measurement (hypersensitivity studies *only*)	200	28	.08	467
Allergy skin tests (hypersensitivity studies *only*)	200	1	1	200
Company interview	40	1	1	40

Dated: January 15, 1997.

William G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–1475 Filed 1–21–97; 8:45 am]

BILLING CODE 4163–18–P

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Comprehensive Child Development Program Management Information System.

OMB No.: 0980–0226.

Description: The Comprehensive Child Development Program (CCDP) provides comprehensive services to low-income families through 10 grantees. Data on the feasibility and management of the program will be collected through the management information (MIS) submitted here. The data will be collected from CCDP

grantee agencies and will continue to be used for (1) research, (2) federal monitoring, and (3) internal project management.

Respondents: Not-for-profit institutions; Individuals or Households; and State, Local or Tribal Government.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Recruitment	566	1	.25	142
New family profile	566	1	.50	283
Updated family profile	2,460	1	.17	418
Development screening/assessment	4,846	.25	.25	1,212
Family needs assessment	2,460	2	.50	2,460
Family service plan	2,460	2	.25	1,230
Contact summary	2,460	50	.12	14,760
Rehabilitative services	8,069	4	.12	3,873
Pregnancy description	418	1	.25	105

Estimated total annual burden hours: 24,483.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: January 15, 1997.

Douglas O. Godesky,

Reports Clearance Officer.

[FR Doc. 97–1497 Filed 1–21–97; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 96N–0454]

Agency Information Collection Activities: Proposed Collections; Comment Request; Reinstatements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish a notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on provisions related to investigational device exemptions (IDE) reports and records; requirements for premarket notifications and summaries filed under the Federal Food, Drug, and Cosmetic Act (the act); and reporting and recordkeeping requirements imposed on entities that have had products detained during an establishment inspection that are believed to be adulterated or misbranded, or have had products banned.

DATES: Submit written comments on the collections of information by March 24, 1997.

ADDRESSES: Submit written comments on the collections of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Judith V. Bigelow, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1479.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collections of information listed below.

With respect to each of the following collections of information, FDA invites comments on: (1) Whether the proposed collections of information are necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of the agency's estimates of the burdens of the proposed collections of information, including the validity of the methodologies and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burdens of the collections of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

1. Investigational Device Exemptions Reports and Records (Part 812 (21 CFR Part 812)) (OMB Control Number 0910–0078—Reinstatement)

This information is collected under the statutory authority of the act regarding investigational devices (section 520(g) (21 U.S.C. 360j(g))). An IDE allows a device, which would otherwise be subject to provisions of the act such as premarket notification or premarket approval, to be used in